DDInter1852 DDInter1592
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Rifapentine
Treprostinil {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Rifapentine
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Rifapentine
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifapentine (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Rifapentine (Compound)
Treprostinil (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Rifapentine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Rifampicin (Compound) and Rifampicin (Compound) resembles Rifapentine (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Treprostinil (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is regulated by DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Rifapentine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)